H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

Original reporting
Published Oct 6, 2026, 11:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$ANIX
Bullish
high confidence
Mentioned
$ANIX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ANIXBullishMed
01

Why it matters

The stable‑disease result could spark short‑term buying, but the long‑term upside depends on further trial milestones.

02

Market read

First‑time disclosure of positive Phase 1 data for ANIX, likely to move the stock in the near term.

03

What to watch

The trial size is very small and the result is a single patient; regulatory timelines remain uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

ANIX is a micro‑cap biotech developing FSHR‑targeted CAR‑T therapies for ovarian cancer and holds a strong cash position.

Company-level read

Ticker impact

$ANIXBullishHigh confidence
Context

ANIX announced stable disease in a Phase 1 CAR‑T trial patient, the first such response reported.

Expected impact

potential upside as market prices in the encouraging trial result

Evidence & confidence

Phase 1 data showing disease stability is rare news for a micro‑cap biotech and can trigger short‑term price pressure.

Market effects

Early CAR‑T success may boost interest in the broader cell‑therapy sector.

Limited to U.S. biotech investors; no broader regional effect.

Minor global impact, confined to biotech and oncology investors.

Counterpoint

Phase 1 data is early and may not translate to later‑stage success; caution against over‑optimism.

Key entities

  • ANIX

    ANIX Biosciences, NASDAQ‑listed biotech.

  • H.C. Wainwright

    Equity research firm reiterating Buy rating.

Related articles

$ANIXMedAI 8/10

Anixa ovarian cancer trial to be presented at ESMO congress

Anixa Biosciences (NASDAQ:ANIX) will present Phase 1 trial results for its ovarian cancer treatment at the ESMO congress. The trial, led by Dr. Robert Wenham, evaluates the safety and efficacy of liraltagene autoleucel, a CAR-T therapy. The company reported no dose-limiting toxicities, stable disease in one patient, and over one-year survival in four patients. Anixa plans to advance to a sixth cohort with a 1,000-fold dose increase.

$ANIXMedAI 8/10

Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham will present Phase 1 trial results of its CAR-T therapy for ovarian cancer at the ESMO Congress in December 2026. The trial, conducted at Moffitt Cancer Center, has completed its fifth cohort with no dose-limiting toxicities and encouraging preliminary results. The company plans to advance to a sixth cohort with a higher dose.

$ANIXMedAI 8/10

Four patients have survived over a year after treatment, one beyond two years. Anixa's trial will be presented Dec. 14.

Anixa Biosciences reported positive interim results from its Phase 1 trial of lira-cel, a CAR-T therapy for ovarian cancer. Four patients survived over a year, one beyond two years. The company plans to advance to a sixth cohort with a 1,000-fold dose increase. Results will be presented at the ESMO Immuno-Oncology & Advanced Therapies Congress on Dec. 14.

$ANIXLowAI 8/10

Anixa completes fifth cohort dosing in ovarian cancer trial

Anixa Biosciences (NASDAQ:ANIX) completed dosing the fifth cohort in its Phase 1 trial for ovarian cancer, with no dose-limiting toxicities observed. The fifth cohort received the highest dose yet, and one patient showed stable disease 90 days post-treatment. The sixth cohort will evaluate an even higher dose. The trial, conducted at Moffitt Cancer Center, aims to assess safety, tolerability, and preliminary efficacy.

$ANIXMedAI 8/10

Four ovarian cancer patients lived over a year after Anixa's experimental treatment.

Anixa Biosciences' experimental ovarian cancer treatment, lira-cel, showed promising results in a Phase 1 trial, with four patients surviving over a year. Dr. Jose Conejo-Garcia, who invented the technology, will present findings at the 2026 Ovarian Cancer Midwest Focus Conference. The trial, conducted with Moffitt Cancer Center, has not reported dose-limiting toxicities, and one patient has survived beyond two years.